Cure Pharmaceutical (OTCMKTS:CURR) Stock Extends Fall: Company Collaborates With Milagro Pharmaceuticals

Shares of Cure Pharmaceutical (OTCMKTS:CURR) continues to trend lower on Friday and fell 29% last week.

Trading Data

On Friday, CURR stock went down 9.10% to $0.25 with more than 187K shares traded, compared to its average volume of 170K shares. The stock moved within a range of $0.2300 – 0.2587 after opening trading at $0.24.

CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico

Developer and manufacturer of innovative delivery formulation for drugs, supplements and wellness products, Cure Pharmaceutical (OTCMKTS:CURR) and Milagro Pharmaceuticals announced collaboration on March 3, 2022. This collaboration will see registration and selling in Mexico several CURE’s OTC and medical compounds.

Cure is discussing number of large distributors in Latin America and Mexico. The OTF products would be sold and marketed in Mexico through significant distribution partners.These include CUREfilm Blue,  an oral soluble form of sildenafil citrate for treating erectile dysfunction, Vitamin D3 – providing weekly 40,000 IU dose of Vitamin D as well as electrolyte energy boost- sugar-free alternative to energy drinks.

Opportunity to serve Latin American market into Mexico is exciting, which will accelerate ramp up of CURE’s FDA-registered, cGMP manufacturing facility. The firm pioneered and developed patented CUREfilm, drug delivery platform and it is expecting distribution partner for LATAM territory in the coming months.

Martin Simon, CEO of Milagro Pharmaceuticals said that the company is excited on working with CURE. Simon added that this would bring forth innovative wellness product as well as proprietary drug forms to Mexico. The intent will be to encompass rest of Latin America, where demand for wellness and health products is surging quickly vis-à-vis other parts of the world.

Key Quote

Martin Simon, CEO of Milagro Pharmaceuticals, stated, “We are pleased to be working with CURE to bring their innovative wellness products and proprietary drug forms and delivery systems to Mexico, with the intention to extend our collaboration to encompass the rest of Latin America where the demand for health & wellness products is growing more rapidly than many other parts of the world.”

Technical Data

CURR stock is trading below the 20-Day and 50-Day Moving averages of $0.34 and $0.34 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.52.